Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
L'entreprise
L'entreprise
Notre histoire
Notre équipe
Carrières
Partenaires
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Accès
Affaires médicales
Accès aux patients
Contactez les affaires médicales
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Ressources
Ressources
Dans la presse
Communiqués de presse
Ressources pour les patients
FAQ
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Investisseurs
Investisseurs
Aperçu pour les investisseurs
Informations financières
Évènements
News
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Oups ! Une erreur s'est produite lors de l'envoi du formulaire.
Merci ! Votre candidature a été reçue !
Oups ! Une erreur s'est produite lors de l'envoi du formulaire.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Other Articles & Publications
Journal of Clinical Oncology
February 14, 2025
,
Sarcoma
Lisez maintenant
Téléchargez maintenant
View Publication
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO)-GI)
January 25, 2025
,
Fakih, et al.
Colorectal (CRC)
Lisez maintenant
Téléchargez maintenant
View Poster
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)
January 25, 2025
,
Ghelardi et al.
Colorectal (CRC)
Lisez maintenant
Téléchargez maintenant
View Poster
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)